Stockholm
-
Sobi Emerges as Savior for CTI Biopharma Cash Crunch With $1.7B M&A Deal
Swedish Orphan Biovitrum is acquiring CTI Biopharma in a $1.7 billion deal centered on the biotech’s commercialized drug for the blood cancer myelofibrosis. Sobi says the drug, Vonjo, complements one of its own assets approved for a different blood disorder.
-
Sobi and Selecta Bio Gout Drug Hits Phase 3 Goals, Paving Way for FDA Submission
Sobi said it plans to seek FDA approval of the gout drug, SEL-212, in 2024. If approved, it would compete against Krystexxa, a Horizon Therapeutics drug projected to become a blockbuster seller.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
US, UK researchers win Nobel Prize for medicine for research on cells’ adaption to oxygen availability
The Nobel Prize in Medicine or Physiology went to Drs. William Kaelin, Gregg Semenza and Peter Ratcliffe. Their research has led to new strategies for treating diseases like cancers and anemia.
-
Sanofi’s billion-dollar multiple sclerosis drug faces competitive threat from Novartis, J&J agents
On Friday, Novartis presented data at ECTRIMS showing that Arzerra had superior efficacy to Sanofi’s Aubagio. Johnson & Johnson’s Janssen division had presented data for its drug, ponesimod, two days before.
-
Oncopeptides looks forward to updates on myeloma drug at European hematology conference
In a phone interview, CEO Jakob Lindberg indicated that data so far showed a study was doing well in terms of progression-free survival.
-
FDA approves Sobi’s Gamifant for rare immune disease
The Swedish drugmaker acquired rights to the drug from Switzerland-based Novimmune in July for about $50 million, plus about $400 million in payments over eight years.
-
AstraZeneca sells US rights to RSV drug to Swedish firm for $1.5B
Sobi buys US rights to Synagis, currently the only drug approved for treating RSV, along with 50 percent of US earnings for its successor, the Phase II MEDI8897.
-
Elekta bets MRI is the next step in radiotherapy
The challenge with radiation and other cancer therapies is getting the right amount of treatment to the tumor and leaving healthy cells unscathed.
-
Swedish design firm Pond Healthcare collaborates with Novartis on smart spirometer
Pond Healthcare Innovation CEO Daniel Taub said in an interview that the Air Smart spirometer device is CE-certified by European regulators and is available in Europe
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
Health IT, Hospitals, Startups
Can a healthcare app globalize one country’s fight against osteoarthritis?
Swedish startup Jojnts has developed a digital version of a national program to help people […]
-
Devices & Diagnostics, Startups
Missouri startup raises near $1M to commercialize novel collagen scaffold for soft tissue therapeutic applications
Dermelle, LLC (aka EternoGen, LLC), a Columbia, Missouri-based startup that works with collagen scaffolds for […]